Phaseline

Targets › HCVNS5A

HCVNS5A: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Infectious disease; next expected readout Mar 2028.

Open in Phaseline: the race on HCVNS5A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Allergy and Infectious Diseases (NIAID)Pibrentasvir
Nonstructural protein 5A inhibitor
HCVNS3, HCVNS5APhase 1Hepatitis CMar 2028

Conditions

Hepatitis C (1)

Modalities

small molecule (1)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (1)

Related targets

HCVNS3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.